IBRX — Immunitybio Cashflow Statement
0.000.00%
Last trade - 00:00- $4.95bn
- $5.53bn
- $0.62m
- 11
- 11
- 100
- 36
Annual cashflow statement for Immunitybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -160 | -224 | -350 | -417 | -584 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 9.65 | 26.3 | 80.3 | 69.6 | 195 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -15.6 | 16.4 | -19.1 | -8 | 3.98 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -152 | -172 | -274 | -338 | -367 |
| Capital Expenditures | -4.29 | -1.67 | -33.6 | -99.4 | -30.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 22.8 | -18.1 | -51.3 | 127 | 0.114 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 18.6 | -19.8 | -84.9 | 27.3 | -30.5 |
| Financing Cash Flow Items | 0 | 0 | 1.02 | -0.397 | -0.077 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 114 | 151 | 505 | 234 | 558 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -19.3 | -40.9 | 146 | -76.3 | 161 |